Summary. Acute hospital-at-home programs that send a hospital-equivalent care team into the patient’s home — with daily clinician visits, on-call response, and a real workflow for escalation — are genuine medicine. CMS’s Acute Hospital Care at Home waiver made the financial structure possible at scale. The clinical question is which patients benefit, and the institutional question is whether the program is being run as care delivery or as a throughput-and-margin play. The two are different, and the patients can tell.
This page is a holding place for a longer case study I am still drafting. The short version: I am cautiously optimistic about the model and skeptical of the marketing. The published outcomes data is encouraging for a narrow patient profile (selected admissions for CHF, COPD exacerbation, cellulitis, UTI, and certain pneumonias in patients with supportive home environments). The published outcomes data does NOT support deploying this as a general overflow strategy when the hospital is full.
What I want to see before I am more confident:
- Long-term readmission and mortality data at scale, not just the favorable cohorts that made it into pilot publications
- Honest accounting of which patients were screened out, and what happened to them
- Caregiver burden data — these programs externalize a real amount of work onto family members
- Equity data — who gets offered hospital-at-home and who gets the inpatient bed
A fuller treatment will appear here.
— Jeremy Tabernero, MD · More case studies · Get in touch